NCT04776447 (APOLO) is a Phase 2 clinical trial of Carboplatin in Lung Diseases, sponsored by Fundación GECP.

Who is sponsoring NCT04776447?

NCT04776447 is sponsored by Fundación GECP.

What drugs are being tested in NCT04776447?

Interventions in NCT04776447: Carboplatin, Placlitaxel, Atezolizumab.

What condition does NCT04776447 study?

NCT04776447 studies Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Respiratory Tract Neoplasms, Carcinoma Bronchiogenic Stage III, Thoracic Neoplasms.

Is NCT04776447 still recruiting?

NCT04776447 is currently active, enrolled. Last updated 9 April 2025.

Last reviewed 2025-04-09 · How we verify

NCT04776447: APOLO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

Active, enrolled Phase 2 Last updated 9 April 2025

What this trial tests

Phase 2 trial testing Carboplatin in Lung Diseases in 38 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

16 June 2021

Primary endpoint
15 November 2026

15 November 2027

Quick facts

Lead sponsor	Fundación GECP
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	16 June 2021
Primary completion	15 November 2026
Estimated completion	15 November 2027
Sites	22 locations across Spain

Drugs / interventions tested

Carboplatin (Carboplatin) — full drug profile →
Placlitaxel — full drug profile →
Atezolizumab (atezolizumab) — full drug profile →

Conditions studied

Lung Diseases — all drugs for Lung Diseases →
Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →
Stage IIIA Non-small Cell Lung Cancer — all drugs for Stage IIIA Non-small Cell Lung Cancer →
Stage IIIB Non-small Cell Lung Cancer — all drugs for Stage IIIB Non-small Cell Lung Cancer →

Sponsor

Fundación GECP — full company profile →

Who can join

Adults 18 to 75, any sex, with Lung Diseases or Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment (Atezolizumab + Induction chemotherapy (CT) + CT-Radiotherapy) in terms of the Progression Free Survival at 12 months

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives.
Césaire M, Montanari J, Curcio H, Lerouge D, et al · · 2022 · cited 35× · PMID 35740495 · DOI 10.3390/cancers14122829
Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.
Wu L, Zhang Z, Bai M, Yan Y, et al · · 2023 · cited 29× · PMID 37221584 · DOI 10.1186/s12964-023-01139-8
Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
Remon J, Levy A, Singh P, Hendriks LEL, et al · · 2022 · cited 12× · PMID 35923929 · DOI 10.1177/17588359221113268
Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients.
Frąk M, Krawczyk P, Kalinka E, Milanowski J. · · 2021 · cited 9× · PMID 33799560 · DOI 10.3390/cancers13061222
Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.
Provencio M, Campos B, Guirado M, Vila L, et al · · 2025 · cited 3× · PMID 41436730 · DOI 10.1038/s41467-025-66097-w
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction Trial.
Smeenk MM, van Diessen JNA, Boellaard TN, Hartemink KJ, et al · · 2025 · cited 2× · PMID 39821070 · DOI 10.1158/1078-0432.ccr-24-3476
Synergistic Action of Immunotherapy and Nanotherapy against Cancer Patients Infected with SARS-CoV-2 and the Use of Artificial Intelligence.
Gupta T, Debele TA, Wei YF, Gupta A, et al · · 2022 · cited 1× · PMID 35008377 · DOI 10.3390/cancers14010213

Verify or expand the search:

Other trials of Carboplatin

Trials testing the same drug.

NCT04832438 — 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma · Phase 2 · withdrawn
NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting

Other recruiting trials for Lung Diseases

Currently open trials in the same condition.

NCT07356076 — The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases · recruiting
NCT07243964 — Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation · recruiting
NCT07270744 — Data Collection Using Eko Devices in a Clinical Setting · recruiting
NCT07227376 — Data Collection Using Eko Digital Devices in a Clinical Setting · recruiting
NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting

Other Fundación GECP trials

Trials by the same sponsor.

NCT07247786 — Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI · Phase 2 · not yet recruiting
NCT07242547 — Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients · Phase 2 · recruiting
NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting
NCT07153445 — Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lu · Phase 2 · recruiting
NCT06431633 — Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04776447 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación GECP
Last refreshed: 9 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04776447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing